Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside - Archive ouverte HAL Access content directly
Journal Articles Oncotarget Year : 2016

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

(1) , (2) , (1, 3) , (1) , (1) , (2) , (2) , (1) , (4, 1) , (1, 4) , (1, 3)
1
2
3
4

Abstract

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.
Fichier principal
Vignette du fichier
PDFEqu14.pdf (6.63 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-01319327 , version 1 (20-05-2016)

Identifiers

  • HAL Id : inserm-01319327 , version 1
  • PUBMED : 27172791

Cite

Julien Fleurence, Denis Cochonneau, Sophie Fougeray, Lisa Oliver, Fanny Geraldo, et al.. Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside. Oncotarget, 2016. ⟨inserm-01319327⟩
233 View
152 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More